News

Coherus Biosciences price target lowered to $1.05 from $1.50 at UBS
UBS analyst Ashwani Verma lowered the firm’s price target on Coherus Biosciences (CHRS) to $1.05 from $1.50 and keeps a Neutral rating on the ...
CPTx Appoints McDavid Stilwell Chief Financial Officer
CPTx GmbH ("CPTx"), a pioneer in the therapeutic development and manufacturing of novel medicines built with single-stranded ...